Bookmark
Forward
QuickView for Lincomycin (compound)
PubChem
| Name: | Lincomycin |
|---|---|
| PubChem Compound ID: | 11418330 |
| Description: | An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections. |
| Molecular formula: | C18H34N2O6S |
| Molecular weight: | 406.538 g/mol |
DrugBank
Identification
| Name: | Lincomycin |
|---|---|
| Name (isomeric): | DB01627 |
| Drug Type: | small molecule |
| Description: | An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections. |
| Synonyms: |
Lincomycin hydrochloride; Lincomyocin; LCM; Lincomycine
|
| Brand: | Lincomix 20, Lincorex, Pura Ject 100, Lincolcina, Lincolnensin, Mycivin, Lincomix, Lincocin, Lincocine |
| Category: | Protein Synthesis Inhibitors, Anti-Bacterial Agents, Lincomycins |
| CAS number: | 154-21-2 |
Pharmacology
| Indication: | Lincomycin is an antibiotic used in the treatment of staphylococcal, streptococcal, and <i>Bacteroides fragilis</i> infections. |
|---|---|
| Pharmacology: |
Lincomycin is a lincosamide antibiotic that comes from the yeast Streptomyces lincolnensis. Lincomycin has been shown to be active in vitro against the following microorganisms: Aerobic gram-positive cocci: Streptococcus pyogenes and Viridans group streptococci; Aerobic gram-positive bacilli: Corynebacterium diphtheriae;...
show more » |
| Mechanism of Action: | Lincomycin inhibits protein synthesis in susceptible bacteria by binding to the 50 S subunits of bacterial ribosomes and preventing peptide bond formation upon transcription. It is usually considered bacteriostatic, but may be bactericidal in high concentrations or when used against highly susceptible organisms. |
| Absorption: | Rapidly absorbed from the gastrointestinal tract following oral administration. Approximately 20 to 30% absorbed orally in fasting state; absorption decreased when taken with food. |
| Protein binding: | Protein binding decreases with increased plasma concentrations. Range, 28 to 86% (average, 70 to 75%). Albumin is not thought to be the primary binding component. |
| Biotransformation: | Presumed hepatic, however metabolites have not been fully characterized. |
| Route of elimination: | Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 3 percent). Tissue level studies indicate that bile is an important route of excretion. |
| Half Life: | The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours. The serum half-life of lincomycin may be prolonged in patients with severe impairment of renal function compared to patients with normal renal function. In patients with abnormal hepatic function, serum half-life may be twofold longer than in patients with normal hepatic function. |
| Affected organisms: | Enteric bacteria and other eubacteria |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
